Search our Database of Scientific Publications and Authors

I’m looking for a

    932 results match your criteria Lupus Erythematosus Drug-Induced

    1 OF 19

    Hydralazine Induced Lupus Syndrome Presenting with Recurrent Pericardial Effusion and a Negative Antinuclear Antibody.
    Case Rep Rheumatol 2017 17;2017:5245904. Epub 2017 Jan 17.
    Department of Internal Medicine, Seton Hall University School of Health and Medical Sciences, Saint Francis Medical Center, Trenton, NJ, USA.
    Drug induced lupus erythematosus (DIL or DILE) is an autoimmune disorder caused by chronic use of certain drugs. We report a unique case of hydralazine induced lupus syndrome (HILS) with a negative antinuclear antibody in a female patient who was on hydralazine for a period of 1.5-2 years and developed recurrent pericardial effusion as a result of it. Read More

    A case of lupus-like syndrome in a patient receiving adalimumab and a brief review of the literature on drug-induced lupus erythematosus.
    J Clin Pharm Ther 2017 Feb 12. Epub 2017 Feb 12.
    Department of Dermatology and Venereology, Medical Faculty and Teaching Hospital Pilsen, Charles University, Pilsen, Czech Republic.
    What Is Known And Objective: Drug-induced lupus erythematosus occurs with some drugs and resolves with their withdrawal. Anti-TNF therapies have been found to be associated with a lupus-like syndrome, which is clinically distinct from classical drug-induced as well as idiopathic lupus erythematosus.

    Case Description: We describe a case of a patient with severe psoriasis, who developed muscle pain with paraesthesia accompanied by ANA titres elevation with adalimumab treatment. Read More

    Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics, Disease Associations, Treatments, and Outcomes in a Series of 90 Patients at Mayo Clinic, 1996-2011.
    Mayo Clin Proc 2017 Feb 6. Epub 2017 Feb 6.
    Department of Dermatology, Mayo Clinic, Rochester, MN. Electronic address:
    Objective: To characterize the clinical presentation, laboratory studies, disease associations, and treatments of subacute cutaneous lupus erythematosus (SCLE).

    Patients And Methods: A retrospective review of 90 patients with SCLE at Mayo Clinic from January 1, 1996, through October 28, 2011, was performed.

    Results: The mean patient age at diagnosis was 61 years; 64 patients (71%) were women, and 11 cases (12%) were drug induced (1996-2000, no drug-induced cases; 2001-2005, 2 cases; 2006-2011, 9 cases). Read More

    [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
    • Authors:
    • ,
    Zhonghua Nei Ke Za Zhi 2017 Jan;56(1):81-85
    Non-steroidal anti-inflammatory drugs (NSAIDs) are a broad class of non glucocorticoid drugs which are extensively used in anti-inflammatory, analgesic, and antipyretic therapies. However, NSAIDs may cause many side effects, most commonly in gastrointestinal(GI) tract. Cardiovascular system, kidney, liver, central nervous system and hematopoietic system are also involved. Read More

    Nuclear Factor Erythroid 2-related Factor 2 Deficiency Exacerbates Lupus Nephritis in B6/lpr mice by Regulating Th17 Cell Function.
    Sci Rep 2016 Dec 12;6:38619. Epub 2016 Dec 12.
    Institute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
    Lupus nephritis (LN) is the major clinical manifestation of systemic lupus erythematosus. LN is promoted by T helper 17 (Th17) cells, which are the major pro-inflammatory T cell subset contributing to autoimmunity regulation. Nuclear factor erythroid 2-related factor 2 (NRF2) is critical for suppressing reactive oxygen species (ROS) and relieving oxidant stress by regulating antioxidant gene expression. Read More

    Rare Occurrence of Drug Induced Subacute Cutaneous Lupus Erythematosus with Leflunomide Therapy.
    J Clin Diagn Res 2016 Oct 1;10(10):OD06-OD07. Epub 2016 Oct 1.
    Intern, Department of Medicine, Pt. BD Sharma PGIMS , Rohtak, Haryana, India .
    Leflunomide is an immunomodulatory drug exhibiting anti-inflammatory, anti-proliferative and immunosuppressive effects. It has been widely used for treatment of active rheumatoid arthritis. Despite its good safety profile cutaneous side effects like alopecia, eczema, pruritis and dry skin have been reported with Leflunomide use. Read More

    Isoniazid Induced Lupus Presenting as Oral Mucosal Ulcers with Pancytopenia.
    J Clin Diagn Res 2016 Oct 1;10(10):OD03-OD05. Epub 2016 Oct 1.
    Professor, Department of Pulmonary Medicine, D.Y. Patil Medical College and Hospital , Mumbai, Maharashtra, India .
    Drug Induced Lupus Erythematous (DILE) is a rare adverse reaction to a large variety of drugs including Isoniazid (INH), with features resembling idiopathic Systemic Lupus Erythematosus (SLE). Diagnosis require identification of a temporal relationship between drug administered and symptom. It is an idiosyncratic reaction, with no pre-existing lupus. Read More

    Treatment of antiviral-resistant recurrent erythema multiforme with dapsone.
    Dermatol Ther 2016 Nov 18. Epub 2016 Nov 18.
    Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL.
    Recurrent erythema multiforme (REM) is a chronic disease characterized by frequent episodes of target cutaneous lesions in an acral distribution. Conventional treatment includes systemic corticosteroids and antiviral therapy. The aim of this study was to evaluate dapsone as a potential steroid sparing-agent for the treatment of REM after a failed trial of at least one antiviral therapy (acyclovir, famciclovir, or valacyclovir). Read More

    Drug-induced cutaneous lupus erythematosus: 88 new cases.
    Eur J Dermatol 2017 Feb;27(1):28-33
    Department of Dermatology and Allergy Centre, Odense University Hospital, DK-5000, Odense C, Denmark.
    Background: An increasing number of drugs have been linked to drug-induced subacute cutaneous lupus erythematosus (DI-SCLE). The recognition and management of DI-SCLE can be challenging, as the condition may be triggered by different classes of drugs after variable lengths of time.

    Objectives: To determine the proportion of patients with cutaneous lupus erythematosus (CLE) whose drugs are an inducing or aggravating factor. Read More

    TNF-alpha antagonist induced lupus on three different agents.
    Postgrad Med 2016 Oct 28:1-3. Epub 2016 Oct 28.
    c Department of Gastroenterology , Lenox hill Hospital , New York , NY , USA.
    Tumor necrosis factor alpha (TNF alpha) antagonists are biologic agents used in the management of inflammatory conditions such as rheumatoid arthritis, seronegative spondyloarthropathies and inflammatory bowel disease. These agents have been recently shown to cause a syndrome called anti-TNF induced lupus (ATIL), a rare condition which has similar clinical manifestations to idiopathic systemic lupus erythematosus (SLE). Given that extra-intestinal manifestations of inflammatory bowel disease include arthritis, it can be difficult to separate arthritis due to underlying disease from drug-induced arthritis. Read More

    Wilson's Disease with Systemic Lupus Erythematosus.
    J Assoc Physicians India 2016 Apr;64(4):81-82
    Professor and Head, Department of General Medicine, Coimbatore Medical College Hospital, Coimbatore, Tamil Nadu.
    Case reports of Wilson's disease occurring in combination with SLE are rarely reported in literature. Drug induced lupus have been observed in patients taking D-penicillamine for Wilson's disease. Here we report a case from Coimbatore Medical College hospital, who presented with fever and neuropsychiatric symptoms as the initial manifestation and found to have both SLE and Wilson's disease on subsequent evaluation. Read More

    Anastrozole-induced subacute cutaneous lupus erythematosus.
    Cutis 2016 Aug;98(2):E22-6
    Northwell Department of Dermatology, Hofstra-Northwell School of Medicine, Hempstead, New York, USA.
    Drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) has been associated with numerous drugs, but there are limited reports of its association with aromatase inhibitor anastrozole. We report the case of a patient undergoing treatment with anastrozole for breast cancer who presented with clinical, serological, and histological evidence consistent with DI-SCLE. Her condition quickly began to improve after the use of anastrozole was discontinued and hydroxychloroquine therapy was initiated. Read More

    [Terbinafine : Drug-induced lupus erythematodes and triggering of psoriatic skin lesions].
    Hautarzt 2016 Sep;67(9):724-31
    , Hofmannstr. 11, 35444, Biebertal, Deutschland.
    Based on the technical information that oral terbinafine must be used with caution in patients with pre-existing psoriasis or lupus erythematosus, the literature was summarized. Terbinafine belongs to the drugs able to induce subcutaneous lupus erythematosus (SCLE)-with a relatively high risk. The clinical picture of terbinafine-induced SCLE may be highly variable and can also include erythema exsudativum multiforme-like or bullous lesions. Read More

    Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Proton Pump Inhibitors.
    Drugs Real World Outcomes 2016 Jun 29;3(2):145-154. Epub 2016 Mar 29.
    The Ohio State University Wexner Medical Center, 410 W 10th Ave, Columbus, OH 43210 USA.
    Subacute cutaneous lupus erythematosus (SCLE) is an autoimmune disease that may be induced by proton pump inhibitors (PPIs) in at-risk populations. The US FDA does not recognize SCLE as an adverse event associated with PPIs. We queried the FDA Adverse Event Reporting System database, which contains adverse event case reports submitted by the public as well as by industry, and analyzed the data to quantify passive pharmacovigilance signals for SCLE associated with PPIs. Read More

    A case of drug-induced lupus erythematosus secondary to trimethoprim/sulfamethoxazole presenting with pleural effusions and pericardial tamponade.
    Lupus 2017 Mar 11;26(3):316-319. Epub 2016 Jul 11.
    Pulmonary, Critical Care and Sleep Medicine Division, The George Washington University, Washington, DC, USA.
    We report a case of drug-induced lupus erythematosus (DILE) secondary to trimethoprim/sulfamethoxazole (TMP/SMX) in a patient with underlying inflammatory bowel disease (IBD). The initial presentation was with febrile pleural and pericardial effusions followed by cardiac tamponade. The patient was treated with a short course of corticosteroids with complete resolution of symptoms. Read More

    Toxic Epidermal Necrolysis-Like Cutaneous Lupus in Pediatric Patients: A Case Series and Review.
    Pediatrics 2016 Jun;137(6)
    Division of Pediatric Dermatology, Departments of Dermatology and Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin;
    Bullous eruptions in patients with underlying systemic lupus erythematosus (LE) can mimic toxic-epidermal necrolysis (TEN), a rapidly progressive mucocutaneous reaction usually associated with medication use. Differentiating between classic drug-induced TEN and TEN-like cutaneous LE is important but difficult. We report a series of 3 patients with pediatric systemic LE who were admitted with severe worsening of skin disease resembling TEN. Read More

    Prevalence, risk factors, management, and treatment outcomes of first-line antituberculous drug-induced liver injury: a prospective cohort study.
    Pharmacoepidemiol Drug Saf 2016 Aug 2;25(8):908-17. Epub 2016 Mar 2.
    Clinic and Research Center of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
    Purpose: Antituberculosis drug-induced liver injury (ATDILI) is one of the most deleterious side effects associated with chemotherapy against tuberculosis (TB). In this study, our objective was to determine the incidence, risk factors, and management of ATDILI and analyze its impact on the treatment outcome in patients receiving standard anti-TB chemotherapy.

    Methods: A prospective cohort study of ATDILI prevalence was conducted in 938 enrolled patients of the 1426 TB cases in Shanghai from March 2011 to September 2012. Read More

    [Clinical analysis of 6 patients with drug-induced lupus].
    Zhonghua Nei Ke Za Zhi 2016 Mar;55(3):211-5
    Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
    Objective: To improve the understanding of drug-induced lupus (DIL) and the differences from systemic lupus erythematosus (SLE).

    Methods: Clinical manifestation and treatment of patients with definite DIL were retrospectively analyzed.

    Results: Six patients with DIL were enrolled in this study, including 4 females and 2 males. Read More

    Immediate and Delayed Hypersensitivity Reactions to Proton Pump Inhibitors: Evaluation and Management.
    Curr Allergy Asthma Rep 2016 Mar;16(3):17
    Department of Medicine, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA, USA.
    PPIs are among the most commonly administered medications in the USA and are generally well tolerated. Immediate and delayed immune-mediated hypersensitivity reactions are rare but increasingly recognized adverse effects of proton pump inhibitors (PPIs). Immediate hypersensitivity reactions can occur due to IgE-mediated hypersensitivity to PPIs and can be evaluated by immediate hypersensitivity skin testing and oral provocation challenge testing. Read More

    Drug Induced Lupus Erythematosus Due to Capecitabine and Bevacizumab Treatment Presenting with Prolonged Thrombocytopenia.
    Rom J Intern Med 2015 Jul-Sep;53(3):282-5
    Drug induced lupus erythematosus (DLE) is a syndrome that is formed by lupus-like symptoms and laboratory characteristics. Capecitabine is an orally administered tumor-selective fluoropyrimidine that acts as a prodrug of 5-Fluorouracil and bevacizumab is an antivascular endothelial growth factor (anti-VEGF) antibody, both are used for the treatment of patients with colorectal cancer. Herein we report the first case of DILE in a 68-year-old woman who presented with arthralgia, myalgia and prolonged thrombocytopenia after receiving capecitabine and bevacizumab combination treatment as palliative treatment for metastatic colon cancer. Read More

    Progress on mechanism of Tripterygium wilfordii-induced liver injury and detoxification mechanism of licorice.
    Zhongguo Zhong Yao Za Zhi 2015 Jul;40(13):2537-41
    Tripterygium wilfordii has exihibited multiple pharmacological activities, such as anti-inflammatory, immune modulation, anti-tumor and anti-fertility. T. wilfordii have been used for the therapy of inflammation and autoimmune diseases including rheumatoid arthritis, immune complex nephritis and systemic lupus erythematosus clinically. Read More

    [DRUG-INDUCED LUPUS CAUSED BY LONG TERM MINOCYCLINE TREATMENT FOR ACNE VULGARIS].
    Arerugi 2015 Sep;64(9):1269-73
    Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University.
    An 18-year-old Japanese girl had received oral minocycline 200mg daily for treatment of acne vulgaris since 16 years old. She had a fever three months before admission, followed by joint pains in her knees, elbows and several proximal interphalangeal joints one month before admission. She was referred to our hospital because of a high serum level of anti-DNA antibody. Read More

    [Drug-induced acute kidney injury].
    Ther Umsch 2015 Dec;72(11-12):717-27
    1 Universitätsklinik für Nephrologie, Hypertonie und Klinische Pharmakologie, Inselspital Bern.
    Due to their physiological function, the kidneys are exposed to high concentrations of numerous drugs and their metabolites, making them vulnerable to drug-related injuries. This article provides an overview of the pathophysiological mechanisms involved in nephrotoxicity, the most common nephrotoxic drugs, and the risk factors for the occurrence of drug-induced acute kidney injuries. NSAIDs, diuretics, ACE inhibitors, and angiotensin II receptor blockers (ARBs} are the most frequent prerenal causes of an acute elevation in creatinine levels. Read More

    Skin Signs of Rheumatoid Arthritis and its Therapy-Induced Cutaneous Side Effects.
    Am J Clin Dermatol 2016 Apr;17(2):147-62
    Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, 41 Avenue Louis Pasteur, Suite 319, Boston, MA, 02115, USA.
    Rheumatoid arthritis (RA) is a systemic inflammatory disorder that primarily affects the joints, but may exhibit extra-articular, including cutaneous, manifestations such as rheumatoid nodules, rheumatoid vasculitis, granulomatous skin disorders, and neutrophilic dermatoses. A large burden of cutaneous disease may be an indication of RA disease activity and the need for more aggressive treatment. Many of the therapeutic agents used to treat RA can also result in cutaneous adverse effects, which pose their own diagnostic and therapeutic challenges. Read More

    Drug-Induced Subacute Cutaneous Lupus Erythematosus in a Patient Receiving Therapy for Chronic Hepatitis C.
    Am J Ther 2016 Nov/Dec;23(6):e1965-e1967
    Department of Medicine, New York Medical College, Metropolitan Hospital Center, New York, NY.
    Hepatitis C infection and its treatment have been associated with extrahepatic manifestations, including different skin conditions. Over the past decades, a greater number of drugs have been implicated as triggers for drug-induced subacute cutaneous lupus erythematosus. We report a case of a 42-year-old Hispanic man who developed a forehead violaceous rash during treatment with pegylated interferon alpha-2a as part of his therapy against hepatitis C infection that subsequently resulted to be subacute cutaneous lupus erythematosus. Read More

    Secondary angle closure glaucoma by lupus choroidopathy as an initial presentation of systemic lupus erythematosus: a case report.
    BMC Ophthalmol 2015 Oct 29;15:148. Epub 2015 Oct 29.
    Department of Ophthalmology, Kyung Hee University Hospital at Gangdong, Kyung Hee University, 892, Dongnam-ro, Gangdong-gu, Seoul, 05278, Korea.
    Background: We present a rare case of secondary angle closure glaucoma due to systemic lupus erythematosus choroidopathy as initial presentation of systemic lupus erythematosus, accompanied by central nervous system vasculitis and uncontrolled nephropathy.

    Case Presentation: A 31-year-old woman presented with decreased visual acuity, nausea, vomiting, fever, and bilateral angioedema-like eyelid swelling. She had persistent dry cough while taking medication for 3 months, and had usual posterior neck pain, which was treated with analgesic medication and Asian medicines. Read More

    [Secondary humoral immunodeficiency in patiens with systemic lupus erythematosus].
    Vnitr Lek 2015 Sep;61(9):778-84
    Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune multisystem disease. The aim of our study was to clarify the frequency of decreased serum immunoglobulin levels in SLE patients. There were evaluated 799 results of serum immunoglobulin levels gained from 157 patients fulfilling revised ACR criteria in the retrospective study. Read More

    Drug-induced systemic lupus erythematosus in a child after 3 years of treatment with carbamazepine.
    Australas J Dermatol 2017 Feb 30;58(1):e20-e22. Epub 2015 Sep 30.
    Department of Dermatology, Fundación Jiménez Díaz, Madrid, Spain.
    Drug-induced lupus erythematosus (DILE) is a less severe variant of systemic lupus erythematosus (SLE) that generally resolves within weeks or months after the withdrawal of the implicated drug. DILE is unusual during childhood, with the most frequent age of presentation being at 50-70 years of age. Among different drugs, most commonly procainamide and hydralazine have been implicated as a cause of DILE. Read More

    Drug-induced lupus erythematosus associated with donepezil: a case report.
    Age Ageing 2015 Nov 28;44(6):1062-3. Epub 2015 Sep 28.
    Alzheimer Evaluation Unit, ASL Napoli Centro, Naples, Italy.
    The possibility that drug-induced lupus erythematosus (DILE) can be induced by donepezil is presented in this clinical case. Donepezil is an inhibitor of acetylcholinesterase used for the treatment of Alzheimer's disease. It is the first time that donepezil causes DILE. Read More

    Coexistence of Fetal Cardiac Malformation and Maternal Drug-Induced Lupus: Is Lamotrigine Safe?
    Am J Ther 2016 Sep-Oct;23(5):e1263-5
    1Division of Neonatology, Aydin Maternity and Children's Hospital, Aydin, Turkey; and 2Departments of Neonatology and 3Pediatric Cardiology, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey.
    Lamotrigine (LTG) is a widely used second-generation antiepileptic drug for long-term therapy of epileptic patients. Although LTG monotherapy during pregnancy is assumed to be relatively safe, teratogenic effects related to LTG has been reported previously. The presence of fetal malformations and maternal drug-induced lupus erythematosus concurrently in a pregnant women using LTG have not been reported before. Read More

    A proposed mechanism for the adverse effects of acebutolol: CES2 and CYP2C19-mediated metabolism and antinuclear antibody production.
    Biochem Pharmacol 2015 Dec 25;98(4):659-70. Epub 2015 Sep 25.
    Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan.
    Acebutolol, a β-adrenergic receptor-blocker, occasionally causes drug-induced lupus erythematosus (DILE). Acebutolol is mainly metabolized to diacetolol. Because metabolic activation has been considered to be related to acebutolol-induced toxicity, we sought to identify the enzymes that are responsible for acebutolol metabolism and investigate their involvement in acebutolol-induced toxicity. Read More

    Ultraviolet light converts propranolol, a nonselective β-blocker and potential lupus-inducing drug, into a proinflammatory AhR ligand.
    Eur J Immunol 2015 Nov 16;45(11):3174-87. Epub 2015 Oct 16.
    Sorbonne Universités, UPMC Univ Paris 06, Inserm UMRS1135, Centre d'Immunologie et des Maladies Infectieuses (Cimi-Paris), 83 Bd de l'hôpital, F-75013, Paris, France.
    UV light and some medications are known to trigger lupus erythematosus (LE). A common mechanism underlying the immunopathologic effect, resulting from exposure to these two seemingly unrelated factors, remains unknown. The aryl hydrocarbon receptor (AhR) plays a key role in the regulation of IL-22 production in humans and can be activated by both xenobiotics and naturally occurring photoproducts. Read More

    Spondyloarthropathy in inflammatory bowel disease patients on TNF inhibitors.
    Intern Med J 2015 Nov;45(11):1154-60
    Gastroenterology and Hepatology Unit, Canberra Hospital, Canberra, Australian Capital Territory, Australia.
    Background: Musculoskeletal symptoms are the most common extra-intestinal manifestation associated with inflammatory bowel disease (IBD). Spondyloarthritis (SpA) is an umbrella term applied to a group of rheumatic diseases with some features in common and others distinct from other inflammatory arthritides.

    Aim: To determine self-reported prevalence of SpA associated musculoskeletal manifestations in an IBD cohort on tumour necrosis factor (TNF) inhibitors using a questionnaire incorporating Assessment of SpondyloArthritis International Society (ASAS) criteria. Read More

    Anti-TNF-α and hydralazine drug-induced lupus.
    An Bras Dermatol 2015 May-Jun;90(3 Suppl 1):125-9
    Instituto de Dermatologia Professor Rubem David Azulay, Santa Casa da Misericórdia do Rio de Janeiro, Rio de Janeiro, RJ, BR.
    Drug-induced lupus is a rare drug reaction featuring the same symptoms as idiopathic lupus erythematosus. Recently, with the introduction of new medicines in clinical practice, an increase in the number of illness-triggering implicated drugs has been reported, with special emphasis on anti-TNF-α drugs. In the up-to-date list, almost one hundred medications have been associated with the occurrence of drug-induced lupus. Read More

    Drug-induced lupus with leukocytoclastic vasculitis: a rare expression associated with adalimumab.
    An Bras Dermatol 2015 May-Jun;90(3 Suppl 1):121-4
    University of Taubaté, Taubaté, SP, BR.
    TNF alpha antagonist-induced lupus-like syndrome is a rare condition which predominantly affects women (4:1). The average age of onset is 46-51 years. It occurs after exposure to TNF alpha antagonist and disappears after discontinuation of such agents. Read More

    Troxis necrosis, a novel mechanism for drug-induced hepatitis secondary to immunomodulatory therapy.
    Exp Mol Pathol 2015 Oct 20;99(2):341-3. Epub 2015 Aug 20.
    Department of Pathology and Medicine, Harbor-UCLA Medical Center, Torrance, CA 90509, United States.
    Objectives: A case of drug-induced hepatitis mediated by troxis necrosis, a form of autoimmune hepatitis, is described.

    Methods: Clinical data, light and electron microscopy of an ultrasound-guided core needle liver biopsy specimen, were examined to investigate the cause of transaminitis in a 26year old male patient on Cellcept and Plaquenil for the treatment of lupus erythematosus. A systematic PUBMED review of troxis necrosis as the underlying mechanism for drug-induced hepatitis was performed. Read More

    Lupus in a patient with cystinosis: is it drug induced?
    Lupus 2015 Nov 28;24(13):1452-4. Epub 2015 Jul 28.
    Department of Pediatric Nephrology-Rheumatology, Hacettepe University Faculty of Medicine, Turkey.
    A 9-year-old girl with a diagnosis of cystinosis since 2 years of age, on cysteamine therapy, presented with complaints of serositis and arthritis, and laboratory tests revealed high antinuclear antibody titers with hypocomplementemia. Kidney biopsy was not consistent with lupus nephritis. With prednisolone treatment her complaints resolved and creatinine level decreased, but on follow-up, serological features of systemic lupus erythematosus (SLE) continued. Read More

    Systemic lupus erythematosus in Crohn's disease: drug-induced or idiopathic?
    Ann Gastroenterol 2015 Jul-Sep;28(3):408-409
    Gastroenterology Department, Tzaneion General Hospital, Piraeus, Greece.
    Coexistence of Crohn's disease (CD) and idiopathic systemic lupus erythematosus (SLE) is very rare. On the other hand, drug-induced lupus erythematosus (DILE) due to anti-tumor necrosis factor (TNF) agents is a relatively more common entity. DILE due to anti-TNF agents and idiopathic SLE share common serologic and epidemiologic characteristics making the differentiation between those two entities difficult. Read More

    Proton pump inhibitor-induced Sweet's syndrome: report of acute febrile neutrophilic dermatosis in a woman with recurrent breast cancer.
    Dermatol Pract Concept 2015 Apr 30;5(2):113-9. Epub 2015 Apr 30.
    Department of Dermatology, University of California San Diego, San Diego, CA, USA.
    Background: Sweet's syndrome, also referred to as acute febrile neutrophilic dermatosis, can either occur as an idiopathic disorder or associated with another condition, including cancer, or induced by exposure to a drug. Proton pump inhibitors selectively inhibit gastric parietal cell H+-K+-adenosine triphosphatase and are most commonly used for the treatment of gastroesophageal reflux disease.

    Purpose: Proton pump inhibitor-associated Sweet's syndrome is described in a woman with recurrent breast cancer. Read More

    Adalimumab-Induced Cutaneous Lupus Erythematosus in a 16-Year-Old Girl with Juvenile Idiopathic Arthritis.
    Pediatr Dermatol 2015 Jul-Aug;32(4):e140-4. Epub 2015 Apr 6.
    Division of Dermatology, Department of Pediatrics, Seattle Children's Hospital, University of Washington, School of Medicine, Seattle, Washington.
    Tumor necrosis factor α (TNF-α) antagonists are used in the treatment of numerous autoimmune conditions. Adalimumab is the first monoclonal antibody to TNF-α and is used to treat juvenile idiopathic arthritis. A growing body of literature associates anti-TNF-α therapies with several adverse dermatologic manifestations, including drug-induced lupus erythematosus (LE). Read More

    Rowell's Syndrome to ds-DNA Negative Lupus Nephritis: A Yet Unreported Progression.
    Indian J Dermatol 2015 Mar-Apr;60(2):215
    Department of Skin and VD, MGM Medical College, Navi Mumbai, India.
    Rowell's syndrome is now identified as a subtype of subacute lupus erythematosus (LE) with erythema multiforme-like skin lesions, positive serum rheumatoid factor, anti-Ro La positivity and speckled pattern of antinuclear antibodies. Here we describe a case of Rowell's syndrome in an 18-year-old female who was found to be ds-DNA negative, who later progressed to develop stage V lupus nephritis (LN) over a course of 4 months. Although extremely rare, most cases of LN are drug induced. Read More

    [Etiologies and clinical features of 19 cases with bilateral acute sensorineural hearing loss].
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2015 Jan;50(1):3-7
    Department of Otorhinolaryngology, Second Hospital of Tianjin Medical University, Tianjin 300211, China.
    Objective: To investigate the etiologies and clinical features for bilateral acute sensorineural hearing loss (bi-ASNHL).

    Methods: The clinical data of 19 cases presenting with bi-ASNHL were retrospectively analyzed, including the clinical features, systemic examinations, laboratory examinations, audiology and radiology results, as well as the prognosis.

    Results: There were 15 non-otologic diseases in 19 patients, accounting for 78. Read More

    [A case of antitubercular drug-induced toxic epidermal necrosis in a systemic lupus erythematosus patient during treatment for pulmonary tuberculosis].
    Kekkaku 2014 Nov;89(11):807-12
    A 48-year-old woman, who had been suffering from systemic lupus erythematosus for one year and receiving steroid therapy, was admitted to our hospital because of pulmonary tuberculosis. The tuberculosis was treated with INH, RFP, EB, and PZA after having doubled the dose of steroid, but terminated three weeks later due to the appearance of erythema exsudativum multiforme. Treatment was resumed with PZA, SM, and LVFX after resolution of the eruption. Read More

    Patient with terbinafine-induced subacute cutaneous lupus erythematosus followed by thalidomide-induced orofacial neuropathy; Beta blocker use, hypertension, and the risk of psoriasis; eczematous reaction to intravenous immunoglobulin; nicolau syndrome after intra-articular glucocorticoid injection; troponin leak associated with drug-induced methemoglobinemia.
    Hosp Pharm 2015 Jan;50(1):13-7
    Chair and Clinical Professor, Department of Pharmacy Practice, Temple University School of Pharmacy , Philadelphia, Pennsylvania ; Clinical Advisor, Institute for Safe Medication Practices , Horsham, Pennsylvania.
    The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA's) MedWatch program (800-FDA-1088). If you have reported an interesting, preventable ADR to MedWatch, please consider sharing the account with our readers. Write to Dr. Read More

    Review of thalidomide use in the pediatric population.
    J Am Acad Dermatol 2015 Apr 21;72(4):703-11. Epub 2015 Jan 21.
    Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut; Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut.
    Thalidomide is resurging in the management of adult rheumatologic skin conditions, especially lupus erythematosus. Although use in pediatric patients is reported since the 1990s, there are no systematic reviews describing treatment in children. Thalidomide has immunomodulatory and anti-tumor necrosis factor-α effects as well as antiangiogenic properties, making it useful for a broad spectrum of inflammatory disorders. Read More

    Drug-induced lupus.
    Expert Opin Drug Saf 2015 Mar 2;14(3):361-78. Epub 2015 Jan 2.
    University of New Mexico Health Sciences Center, Department of Molecular Genetics and Microbiology , Albuquerque, NM 87131 , USA +1 505 272 4640 ; +1 505 272 9550 ;
    Introduction: Drug-induced lupus (DIL) refers to an idiosyncratic side effect of numerous, apparently unrelated, medications, in which symptoms overlap with those of systemic lupus erythematosus. DIL is reversible by discontinuation of the medication. The etiological mechanism underlying DIL is linked to the inherent susceptibility of the adaptive immune system to lapse into auto-reactivity. Read More

    Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment.
    Can J Cardiol 2014 Dec 23;30(12):1706-15. Epub 2014 Aug 23.
    Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada; Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada. Electronic address:
    Drug-induced heart and vascular disease remains an important health burden. Hydroxychloroquine and its predecessor chloroquine are medications commonly used in the treatment of systemic lupus erythematosus, rheumatoid arthritis, and other connective tissue disorders. Hydroxychloroquine interferes with malarial metabolites, confers immunomodulatory effects, and also affects lysosomal function. Read More

    1 OF 19